In 2017, European Leukemia Net revised the prognostic model for AML by adding RUNX1 and ASXL1 mutations to the previously identified molecular risk categories, which included mutations in NPM1, CEBPA, FLT3–ITD and TP53. This evidence concerns the gene FLT3 and acute myeloid leukemia.